In addition, PA is the enzymatic product of FASN, the increased availability of de novo synthesized PA has been directly linked to the invasive advantage of prostate cancer cells.[76] Therefore, blocking the activity of FASN in PA‐driven tumor metastasis might be an attractive therapeutic pathway. This evidence concerns the gene FASN and prostate carcinoma.